Acrivon Therapeutics (ACRV) EBT (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly EBT of -$22.5 million for Q1 2026, up 12.1% year-over-year from -$20.1 million in Q1 2025, and down 6.35% quarter-over-quarter from -$21.2 million in Q4 2025.
Acrivon Therapeutics (ACRV) EBT (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported EBT for 6 consecutive years, with -$22.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 12.1% year-over-year to -$22.5 million; the TTM figure through Mar 2026 stood at -$86.9 million (up 21.84% YoY), while the FY2025 annual figure was -$85.4 million, up 41.44% from the prior year.
- EBT fell to -$22.5 million in Q1 2026 per ACRV's latest filing, from -$21.2 million in the prior quarter.
- Across five years, EBT topped out at -$5.9 million in Q2 2022 and bottomed at -$35.1 million in Q1 2023.
- Historically, EBT has averaged -$22.6 million across 5 years, with a median of -$23.1 million in 2025.
- Annual changes were most pronounced in 2022 — EBT slumped 496.48% — and 2025, when it surged 40.09%.
- Acrivon Therapeutics' EBT stood at -$10.2 million in 2022, then slumped by 108.42% to -$21.4 million in 2023, then fell by 19.21% to -$25.5 million in 2024, then advanced by 16.84% to -$21.2 million in 2025, then declined by 6.35% to -$22.5 million in 2026.
- Business Quant data shows ACRV's EBT at -$22.5 million in Q1 2026, -$21.2 million in Q4 2025, and -$20.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 81.49 Mn |
| 10 | Acrivon Therapeutics | 91.42 Mn | 91.42 Mn | - | -17.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.93 Mn |
| Mar 31, 2026 | -22.51 Mn |
| Dec 31, 2025 | -21.17 Mn |
| Sep 30, 2025 | -20.18 Mn |
| Jun 30, 2025 | -23.05 Mn |
| Mar 31, 2025 | -25.61 Mn |
| Dec 31, 2024 | -25.45 Mn |
| Sep 30, 2024 | -33.69 Mn |
| Jun 30, 2024 | -26.44 Mn |
| Mar 31, 2024 | -27.10 Mn |
| Dec 31, 2023 | -21.35 Mn |
| Sep 30, 2023 | -28.28 Mn |
| Jun 30, 2023 | -35.02 Mn |
| Mar 31, 2023 | -35.11 Mn |
| Dec 31, 2022 | -10.25 Mn |
| Sep 30, 2022 | -15.93 Mn |
| Jun 30, 2022 | -5.93 Mn |
| Mar 31, 2022 | -7.21 Mn |
| Dec 31, 2021 | -6.28 Mn |
| Sep 30, 2021 | -2.67 Mn |